Relapsed Adult AML: Clinical Trials

23 trials for Relapsed Adult AML, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 recruiting, 4 completed, 4 unknown, 3 withdrawn. 14 Phase 1, 12 Phase 2, 1 Not applicable, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 114Recruiting 5, Completed 3, Withdrawn 3, Unknown 2, Terminated 1
Phase 212Recruiting 4, Unknown 3, Withdrawn 2, Active not recruiting 1, Completed 1, Not yet recruiting 1
Not applicable1Recruiting 1
Phase 31Unknown 1

Follow Relapsed Adult AML: new trials by email Literature Review of Relapsed Adult AML trials Research Report on Relapsed Adult AML

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Menin-Inhibitor Targeted Maintenance in AML
Revumenib, Placebo - Relapsed Adult AML, Stem Cell Transplant Complications
Phase 2Not yet recruitingCenter for International Blood and Marrow Transplant Research1462026-12-012026-06-22
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML
Phase 1 / Phase 2RecruitingMasonic Cancer Center, University of Minnesota182026-05-082026-05-19
Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19
CAR-T cell therapy - Relapsed Adult AML
Phase 1RecruitingUniversity Hospital, Lille52025-07-102025-12-05
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
zelenirstat - Relapsed Adult AML
Phase 1RecruitingPacylex Pharmaceuticals352025-03-032025-03-10
Tislelizumab with Azacitidine in the Treatment of R/R AML
Aza, tislelizumab - Refractory AML, Relapsed Adult AML
Phase 1 / Phase 2WithdrawnInstitute of Hematology & Blood Diseases Hospital, China2024-10-052024-09-19
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level 1 - Relapsed Adult AML, Refractory AML
Phase 1WithdrawnMedical College of Wisconsin2024-08-312024-08-13
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
anti-CLL-1 CAR NK cells - Relapsed Adult AML, Refractory AML
Phase 1RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine242024-04-012025-09-30
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML
Phase 2RecruitingFrench Innovative Leukemia Organisation332024-01-132025-03-24
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
Plerixafor - Relapsed Adult ALL, Relapsed Adult AML
Phase 2UnknownThe First Hospital of Jilin University282023-09-012023-11-21
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Lintuzumab-Ac225, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Relapsed Adult AML
Phase 1 / Phase 2WithdrawnActinium Pharmaceuticals2023-03-012023-07-20
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Specialty Palliative Care, Primary Palliative Care - Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia
Not applicableRecruitingMassachusetts General Hospital23002022-06-012025-07-25
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
venetoclax combining chidamide and azacitidine (VCA) - Leukemia, Myeloid, Acute, Relapsed Adult AML
Phase 2RecruitingThe First Affiliated Hospital of Xiamen University302022-01-122025-09-11
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
CAHAG regimen, Placebo regimen - Acute Myeloid Leukemia, Refractory Acute Leukemia
Phase 2Active not recruitingThe First Affiliated Hospital of Soochow University212021-09-012026-03-19
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
Refractory AML, Relapsed Adult AML
CompletedFrench Innovative Leukemia Organisation1772021-07-052023-05-24
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML
Visilizumab - Immunotherapy, Refractory Leukemia
Phase 3UnknownThe First Affiliated Hospital of Soochow University302021-05-012021-12-03
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
LP-108, LP-108 and azacitidine - AML/MDS, CMML
Phase 1CompletedNewave Pharmaceutical Inc322020-07-062026-01-23
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
Venetoclax Oral Tablet - Relapsed Adult AML, Refractory AML
Phase 1 / Phase 2CompletedTechnische Universität Dresden552020-04-062026-09-02
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
CYNK-001 - Leukemia, Leukemia, Myeloid
Phase 1TerminatedCelularity Incorporated272020-03-122024-12-12
Venetoclax and Lintuzumab-Ac225 in AML Patients
Lintuzumab-Ac225, Venetoclax, Spironolactone - Acute Myeloid Leukemia, Relapsed Adult AML
Phase 1 / Phase 2UnknownActinium Pharmaceuticals382020-01-152023-08-04
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Gemtuzumab Ozogamicin 3 mg/m^2, Gemtuzumab Ozogamicin 2 mg/m^2, Pracinostat - 45 mg - Relapsed Adult AML
Phase 1CompletedMedical College of Wisconsin142019-05-242022-06-30

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (23)  ·  Recurrence (4)  ·  Leukemia (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Hematologic Neoplasms (2)  ·  Hematologic Diseases (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Myeloid (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Multiple Myeloma (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasm, Residual (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)

Broader conditions

Hemic and Lymphatic Diseases (23)  ·  Hematologic Diseases (22)  ·  Leukemia, Myeloid (22)  ·  Neoplasms (22)  ·  Neoplasms by Histologic Type (22)  ·  Leukemia (20)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Disease Attributes (4)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Leukemia, Lymphoid (3)  ·  Lymphatic Diseases (3)  ·  Lymphoproliferative Disorders (3)  ·  Bone Marrow Diseases (2)

Interventions

Azacitidine (6)  ·  venetoclax (5)  ·  Cytarabine (2)  ·  Cladribine (1)  ·  Cyclophosphamide (1)  ·  Filgrastim (1)  ·  Gemtuzumab (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Homoharringtonine (1)  ·  Immunotherapy, Adoptive (1)  ·  Infusions, Intravenous (1)  ·  Interleukin-2 (1)  ·  Mitoxantrone (1)  ·  SB939 compound (1)  ·  Spironolactone (1)

Sponsors

Actinium Pharmaceuticals (2)  ·  French Innovative Leukemia Organisation (2)  ·  Medical College of Wisconsin (2)  ·  The First Affiliated Hospital of Soochow University (2)  ·  Agios Pharmaceuticals, Inc. (1)  ·  Aptose Biosciences Inc. (1)  ·  Celularity Incorporated (1)  ·  Center for International Blood and Marrow Transplant Research (1)  ·  Ciusss de L'Est de l'Île de Montréal (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  Massachusetts General Hospital (1)  ·  Newave Pharmaceutical Inc (1)  ·  Pacylex Pharmaceuticals (1)  ·  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)

Countries

United States (9)  ·  China (6)  ·  France (3)  ·  Germany (2)  ·  Spain (2)  ·  Australia (1)  ·  Canada (1)  ·  New Zealand (1)  ·  South Korea (1)

Top investigators

Avinash Desai, MD (2)  ·  Areej El-Jawahri, MD (1)  ·  Bing Xu (1)  ·  Denis-Claude Roy, MD PhD (1)  ·  Guru Subramanian Guru Murthy, MD, MS (1)  ·  Han Yue, Ph.D (1)  ·  Ibrahim Yakoub-Agha, MD,PhD (1)  ·  Jennifer Temel, MD (1)  ·  Long Su, PhD (1)  ·  Naval Daver, MD (1)  ·  Naveen Pemmaraju (1)  ·  Sameem Abedin, MD (1)  ·  Sharmila Koppisetti, M.D (1)

Results publications

PMID 33347715, PMID 38715059, PMID 39665627, PMID 41791831

NIH funding

2023 (2)